Ultrasound contrast developer Andaris of Nottingham, UK, has filed an investigational new drug (IND) application with the Food and Drug Administration to begin phase II clinical trials for cardiac indications of its Quantison agent. The application
Ultrasound contrast developer Andaris of Nottingham, UK, has filed an investigational new drug (IND) application with the Food and Drug Administration to begin phase II clinical trials for cardiac indications of its Quantison agent. The application covers the use of Quantison for left ventricular opacification as well as myocardial perfusion indications. Quantison consists of air-filled albumin microcapsules developed for intravenous imaging (SCAN 2/5/97).
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Shaping the Future of Radiology in 2025: Trends, Threats, and Opportunities
January 10th 2025How do we respond to challenges with staff recruitment, cybersecurity, and looming hospital takeovers in radiology? This author assesses key trends in radiology and offers key insights to stay competitive in the field.